Form 4: Vaxcyte SVP Mikhail Eydelman Executes Option and Sells Shares Under 10b5-1 Plan

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 1, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 5,500 shares of common stock at a price of $21.41 per share.
• On the same day, Eydelman sold 1,414 shares at a weighted average price of $113.381, 3,056 shares at a weighted average price of $114.369, and 1,030 shares at a weighted average price of $115.012.
• These sales were executed under a Rule 10b5-1 trading plan adopted on June 11, 2024.
• Following these transactions, Eydelman directly owns 28,623 shares of common stock and 174,497 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock option exercises and sales.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the insider's trading activity is pre-planned and not based on current, non-public information. It is common for executives to use these plans to diversify their holdings and manage personal finances.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies, especially among executives who receive stock options as part of their compensation.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, aligning with SEC regulations and industry best practices.
• Comparable companies like Moderna (MRNA) and BioNTech (BNTX) also see regular Form 4 filings from their executives, reflecting similar patterns of stock option exercises and sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The insider's actions could be interpreted as a lack of confidence in the company, although the use of a 10b5-1 plan mitigates this concern.

Key Dates